{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:28:38Z","timestamp":1786991318518,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jaip.2020.06.054","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T12:19:06Z","timestamp":1594642746000},"page":"3557-3564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Fracture Risk Reduction by Bisphosphonates in Mastocytosis?"],"prefix":"10.1016","volume":"8","author":[{"given":"Merel C.","family":"Onnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper J.","family":"van Doormaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"van der Veer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris B.","family":"Versluijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke N.G.","family":"Oude Elberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2020.06.054_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.iac.2014.02.003","article-title":"Diagnostic criteria and classification of mastocytosis in 2014","volume":"34","author":"Akin","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2020.06.054_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaip.2020.06.054_bib3","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00198-016-3539-1","article-title":"Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis","volume":"27","author":"Rossini","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jaip.2020.06.054_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis","volume":"67","author":"Van Der Veer","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.06.054_bib5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.iac.2014.01.011","article-title":"Bone involvement and osteoporosis in mastocytosis","volume":"34","author":"Rossini","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2020.06.054_bib6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2014.05.003","article-title":"Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis","volume":"134","author":"Van Der Veer","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.06.054_bib7","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2020.06.054_bib8","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis","volume":"49","author":"Rossini","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jaip.2020.06.054_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11154-016-9362-3","article-title":"Endocrine manifestations of systemic mastocytosis in bone","volume":"17","author":"Greene","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jaip.2020.06.054_bib10","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2353\/ajpath.2009.080871","article-title":"Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts","volume":"174","author":"Biosse-Duplan","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaip.2020.06.054_bib11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaci.2013.06.019","article-title":"Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis","volume":"132","author":"Rabenhorst","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.06.054_bib12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00223-017-0241-z","article-title":"Denosumab for the treatment of mastocytosis-related osteoporosis: a case series","volume":"100","author":"Orsolini","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jaip.2020.06.054_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.06.054_bib14","first-page":"CD001155","article-title":"Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2020.06.054_bib15","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.6004\/jnccn.2018.0088","article-title":"Systemic mastocytosis, version 2.2019 clinical practice guidelines in oncology","volume":"16","author":"Gotlib","year":"2018","journal-title":"J\u00a0Natl Compri Canc Netw"},{"key":"10.1016\/j.jaip.2020.06.054_bib16","doi-asserted-by":"crossref","first-page":"1127.e1","DOI":"10.1016\/j.amjmed.2014.06.015","article-title":"Zoledronic acid in osteoporosis secondary to mastocytosis","volume":"127","author":"Rossini","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2020.06.054_bib17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s10067-006-0369-0","article-title":"Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis","volume":"26","author":"Laroche","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaip.2020.06.054_bib18","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.amjmed.2011.02.038","article-title":"Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis","volume":"124","author":"Laroche","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2020.06.054_bib19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/8756-3282(87)90014-7","article-title":"Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption","volume":"8","author":"Cundy","year":"1987","journal-title":"Bone"},{"key":"10.1016\/j.jaip.2020.06.054_bib20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/ard.2004.029116","article-title":"Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment","volume":"64","author":"Lim","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2020.06.054_bib21","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2020.06.054_bib22","series-title":"WHO scientific group on the assessment of osteoporosis at primary health care level","first-page":"1","year":"2007"},{"key":"10.1016\/j.jaip.2020.06.054_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161435.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142016","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jaip.2020.06.054_bib24","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00198-008-0599-x","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jaip.2020.06.054_bib25","first-page":"452","article-title":"NHG-standard fracture prevention","volume":"55","author":"Elders","year":"2012","journal-title":"Huisarts Wet"},{"key":"10.1016\/j.jaip.2020.06.054_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s001980170112","article-title":"The burden of osteoporotic fractures: a method for setting intervention thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jaip.2020.06.054_bib27","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jaip.2020.06.054_bib28","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00198-010-1338-7","article-title":"The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis","volume":"22","author":"Arends","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jaip.2020.06.054_bib29","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jaci.2014.05.047","article-title":"Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects","volume":"135","author":"Vos","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.06.054_bib30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jaip.2020.06.054_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jaip.2020.06.054_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jaip.2020.06.054_bib33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaci.2013.02.019","article-title":"KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis","volume":"132","author":"Broesby-Olsen","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.06.054_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000091172","article-title":"Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis","volume":"139","author":"Kushnir-Sukhov","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2020.06.054_bib35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-019-03119-3","article-title":"An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis","volume":"146","author":"Riffel","year":"2020","journal-title":"J\u00a0Cancer Res Clin Oncol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820306966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820306966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:28:24Z","timestamp":1761974904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219820306966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2213219820306966"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2020.06.054","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fracture Risk Reduction by Bisphosphonates in Mastocytosis?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2020.06.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}